FASN and neoplasm: In cancerous diseases, TRIM21 has been shown to facilitate tumor lipid metabolism via mediating ubiquitination and degradation of fatty acid synthase (FASN), one of the rate-limiting enzymes in the de novo lipogenesis pathway [19, 20].